Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics C... (the Class Period. Once the truthbehind R...)

Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation

Date:2/5/2008

the Class Period. Once the truth behind Reys was revealed, CellCyte shares plunged 55% in unusually heavy trading on January 8 and 9. The stock fell as low as $2.15 on January 9, 2008, down from a high of $7.02 just days before.

Plaintiff seeks to recover damages on behalf of Class members and is represented by Finkelstein Thompson LLP. Finkelstein Thompson LLP has spent almost three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, in the past decade, the firm has served leadership roles in cases that have recovered over $1 billion for investors and consumers.

If you are a member of the class, you may request that the Court appoint you as lead plaintiff by no later than March 14, 2008. A lead plaintiff is a class member appointed by the Court to direct the litigation on behalf of the class. Although a class member need not be appointed as a lead plaintiff to receive a proportionate share of any proceeds of the litigation, lead plaintiffs make important decisions that could affect the prosecution of the class claims, including decisions concerning settlement. The securities laws create a rebuttable presumption that the plaintiff with the largest financial interest in the litigation is the most adequate to serve as a lead plaintiff. Any member of the purported class may move the Court to serve as lead plaintiff through the counsel of their choice and returning a form to counsel or communicating with counsel is not necessary to participate in any recovery.

If you are a CellCyte shareholder and wish to discuss the case, please contact our Washington, D.C. office toll-free at (877) 337-1050, or by email at contact@finkelsteinthompson.com.

0

GOOD

Page: 1 2
Related biology technology :

1. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
2. MHA Announces: Tommy Thompson to be Keynote Speaker at The MHA 5th Annual Business Summit
3. SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors
4. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
5. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
6. CardioTech Announces Conference Call on February 12 at 2:30 PM Eastern for Third Quarter of Fiscal 2008
7. NeoStem Announces NY State License for Adult Stem Cell Collection
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
10. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation

Post Your Comments:

Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics C...(the Class Period. Once the truthbehind R...)